PEMAZA
MRD-guided treatment with pembrolizumab and azacitidine in NPM1mut AML patients with an imminent hematological relapse
Studienleiter | Prof. Dr. med. Platzbecker |
---|---|
EudraCT-Nr. | 2017-004110-25 |
Studientyp | Phase II |
Indikation | AML |
ClinicalTrial | NCT03769532 |